Streetbeat News

Earnings

MOND

Mondee forecasts its FY23 net revenue to be approximately $210 million, which is below the estimated $244.96 million. The company also expects its adjusted EBITDA to be around $25 million for the same period.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 12:12 pm

ITRM

Iterum Therapeutics reported Q3 losses of $(1.20) per share, missing the consensus estimate of $(0.91) by 31.87%. This represents a 179.07% increase in losses from the same period last year. The company has $35.9M in cash and equivalents.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 12:10 pm

TSVT

2seventy bio (NASDAQ:TSVT) reported Q3 earnings with an EPS of $-1.0, missing estimates by 3.09% compared to the expected $-0.97. Revenue decreased by $1.37 million from the same period last year. In the previous quarter, the company beat EPS estimates which led to a 4.98% share price increase the following day. Historical earnings and revenue figures were also provided for comparison.

Portfolio Pulse from Benzinga Insights

November 14, 2023 | 12:10 pm

ITRM

Iterum Therapeutics (NASDAQ:ITRM) reported Q3 earnings with an EPS of $-1.2, missing estimates by 31.87% compared to the expected $-0.91. Revenue was unchanged from the same period last year. Previously, the company beat EPS estimates by $0.03, which led to a 7.92% share price increase the following day.

Portfolio Pulse from Benzinga Insights

November 14, 2023 | 12:10 pm

FATH

Fathom Digital Mfg (NYSE:FATH) reported Q3 earnings with an EPS of $-2.04, missing estimates by 104% and a revenue decrease of $8.75 million from the previous year. Despite missing last quarter's EPS estimate, the stock increased by 7.04% the following day. The company's past earnings performance shows mixed results with both hits and misses on EPS and revenue estimates.

Portfolio Pulse from Benzinga Insights

November 14, 2023 | 12:10 pm

TSVT

2seventy Bio has announced that it will not meet its original revenue guidance of $470M-$570M for 2023. The company expects that competitive dynamics will continue to negatively affect Abecma sales in Q4.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 12:10 pm

BCLI

Brainstorm Cell (NASDAQ:BCLI) reported Q3 earnings with an EPS of $-0.03, surpassing the estimate of $-0.14 by 78.57%. However, revenue was the same as the previous year's same quarter. Despite beating last quarter's EPS estimates, the share price fell by 6.59% the following day.

Portfolio Pulse from Benzinga Insights

November 14, 2023 | 12:10 pm

RNLX

Renalytix (NASDAQ:RNLX) reported Q1 earnings with an EPS of $-0.11, missing estimates by 10.0% and a revenue decrease of $510 thousand from the previous year. The company's past earnings performance shows mixed results with both beats and misses on EPS estimates.

Portfolio Pulse from Benzinga Insights

November 14, 2023 | 12:10 pm

GRTX

Galera Therapeutics (NASDAQ:GRTX) reported Q3 earnings with an EPS of $-0.33, beating estimates by 17.5% but with no change in revenue from the same period last year. The previous quarter's earnings miss resulted in a 10.03% share price drop the following day.

Portfolio Pulse from Benzinga Insights

November 14, 2023 | 12:10 pm

MOND

Mondee Holdings (MOND) reported Q3 adjusted EPS of $(0.10), slightly better than the $(0.11) estimate, but experienced a 25% decrease from the previous year's $(0.08) per share. Sales for the quarter were $54.53M, missing the $65.25M estimate by 16.43%, despite being a 34.60% increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 12:10 pm